Creoptix develops and markets analytical instruments for drug discovery: highest-sensitivity at low complex components.
Drugs work by binding to their drug target. To analyse this binding is therefore key for the pharmaceutical industry. The sensitivity of current methods is however often limiting. Based on proprietary and patented disruptive technology, Creoptix has developed its first product, QUBE, a system of instrument and disposables achieving highest-sensitivity at low complex components. Qube will be launched by end of 2013.